कृपया अन्य खोज का प्रयास करें
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Garo H. Armen | 69 | 2017 | Executive Chairman |
Brian J. Corvese | 64 | 2017 | Independent Director |
Barbara A. Ryan | 62 | 2021 | Independent Director |
Jennifer Buell | 46 | 2021 | President, CEO & Director |
Ulf Arne Wiinberg | 65 | 2017 | Independent Director |
Lydia Lynch | - | - | Member of the Scientific Advisory Board |
Peter Behner | 59 | 2021 | Independent Director |
Manuel Hidalgo | 55 | - | Member of the Scientific Advisory Board |
Robert Benjamin Stein | 72 | - | Member of the Scientific Advisory Board |
Mark A. Exley | - | - | Member of the Scientific Advisory Board |
Marcela V. Maus | 46 | - | Member of the Scientific Advisory Board |
Jenny Gumperz | - | - | Member of the Scientific Advisory Board |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है